Related references
Note: Only part of the references are listed.Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
Huihui Li et al.
JOURNAL OF NEUROLOGY (2020)
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
Yasuo Oshima et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
Yasuo Oshima et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Factors associated with dimethyl fumarate-induced lymphopenia
Susana Sainz de la Maza et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2019)
Dimethyl fumarate, a two-edged drug: Current status and future directions
Nathaniel Edward Bennett Saidu et al.
MEDICINAL RESEARCH REVIEWS (2019)
Effect of dimethyl fumarate on lymphocytes in RRMS Implications for clinical practice
Devangi Mehta et al.
NEUROLOGY (2019)
A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence
Martin Diebold et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis
Edoardo Galli et al.
NATURE MEDICINE (2019)
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Tomas Kalincik et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US
Daniel Ontaneda et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Treatment response to dimethyl fumarate is characterized by disproportionate CD8+T cell reduction in MS
Vinzenz Fleischer et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
Silvia Medina et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
Erin E. Longbrake et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Treatment response to dimethyl fumarate is characterized by disproportionate CD8+T cell reduction in MS
Vinzenz Fleischer et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
Silvia Medina et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
Erin E. Longbrake et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
Rosa C. Lucchetta et al.
CNS DRUGS (2018)
Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis
Martin Diebold et al.
JOURNAL OF AUTOIMMUNITY (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Fingolimod vs dimethyl fumarate in multiple sclerosis A real-world propensity score-matched study
Luca Prosperini et al.
NEUROLOGY (2018)
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
Alexander Rae-Grant et al.
NEUROLOGY (2018)
Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity
Michael D. Kornberg et al.
SCIENCE (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
Elizabeth A. Mills et al.
FRONTIERS IN NEUROLOGY (2018)
Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies
Gwendoline Montes Diaz et al.
AUTOIMMUNITY REVIEWS (2018)
Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)
Ralf Gold et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
Brandi Vollmer et al.
NEUROLOGY-CLINICAL PRACTICE (2018)
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis
Robert J. Fox et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis
Rui Li et al.
JOURNAL OF IMMUNOLOGY (2017)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
E. Havrdova et al.
EUROPEAN JOURNAL OF NEUROLOGY (2017)
Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients
Qi Wu et al.
JOURNAL OF IMMUNOLOGY (2017)
Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
Eline Huisman et al.
BMJ OPEN (2017)
Classifying PML risk with disease modifying therapies
Joseph R. Berger
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Dimethyl fumarate alters B-cell memory and cytokine production in MS patients
Matthew D. Smith et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2017)
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM
Oscar Fernandez et al.
CLINICAL THERAPEUTICS (2017)
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database
Aaron Boster et al.
NEUROLOGY AND THERAPY (2017)
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis
Mark S. Freedman et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
Emer Fogarty et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS
Benedetta Parodi et al.
ACTA NEUROPATHOLOGICA (2015)
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
John O'Gorman et al.
CLINICAL THERAPEUTICS (2015)
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Thorsten Rosenkranz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison
Michael Hutchinson et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE
Hui Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
ATLAS OF MULTIPLE SCLEROSIS 2013: A GROWING GLOBAL PROBLEM WITH WIDESPREAD INEQUITY
Paul Browne et al.
NEUROLOGY (2014)
Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers
Sarah I. Sheikh et al.
CLINICAL THERAPEUTICS (2013)
Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects
Ralf A. Linker et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM
Eva Havrdova et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action
R. Gold et al.
CLINICAL IMMUNOLOGY (2012)
Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling
Haiyan Peng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Ludwig Kappos et al.
LANCET (2008)
Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1
Joachim C. U. Lehmann et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Oral fumaric acid esters for the treatment of active multiple sclerosis:: an open-label, baseline-controlled pilot study
S. Schimrigk et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Medical progress: Multiple sclerosis.
JH Noseworthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
